Cardio Diagnostics Holdings Inc Sponsors the Illinois Association of Medicaid Health Plan’s Annual Conference

CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring the Illinois Association of Medicaid Health Plans’ (IAMHP) Annual Conference entitled “Bringing Equity into Focus.” The conference is taking place this week, November 14-16, 2022, at the Hyatt Lodge Hotel in Oakbrook. As part of Cardio Diagnostics’ sponsorship, Meesha Dogan, PhD, CEO, is presenting on How to Optimize Health Equity Initiatives at the Population Health Level.

IAMPH’s conferences are among the Medicaid industry’s leading events covering provider, payer, and patient-centered concerns for vulnerable populations. This annual meeting brings together key Medicaid stakeholders across Illinois to discuss critical patient, equity, and reimbursement considerations.

As Dr. Dogan will note in her presentation, “Thinking about health equity, especially in the context of chronic diseases, is critical as undiagnosed and untreated chronic conditions are responsible for high morbidity and costly utilization.”

The conference’s theme this year is to challenge Medicaid plans, state organizations, and medical technology vendors to optimize and actualize health equity. “So, when we focus on equitable access to care and equitable access to high-quality clinical care, we can actually help drive down the population incidence of chronic conditions and as a result reduce the consumption of healthcare resources while improving health outcomes,” shared Dr. Dogan.

About Cardio Diagnostics

Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine^TM (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “should,” “believe,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development and commercialization of products and services, the potential benefits and impact of the Company’s products and services, potential regulatory approvals, and the size and potential growth of current or future markets for the Company’s products and services. Forward-looking statements are statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this press release, and are not intended to serve as, and they must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that Epi+Gen CHD™, Cardio’s initial test, is accepted and adopted by patients, healthcare professionals and participants in other key channels; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s common stock on Nasdaq; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its tests, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that could serve the same or similar functions as the Company’s products and services; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical tests conducted using the Company’s products and services; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Contacts

Investors:

Meesha Dogan, Ph.D.

CEO

855-226-9991

[email protected]

Media & Public Relations:

Khullani Abdullahi

[email protected]